Uloric: first new option for gout in more than 40 yearsTakeda Canada will soon be introducing Uloric (febuxostat 80 mg) tablets, the first new drug to be marketed for gout in more than four decades. Men and Women's Health 2010: OsteoporosisNew developments in therapy, vitamin D requirements, bisphosphonate safety and risk assessment. Actemra: anaphylaxis risk Hoffmann-La Roche and Health Canada warn about potential risk of fatal anaphylaxis with Actemra (tocilizumab). Arthritis care benefits from team approach Leading Ontario clinic spreading its model of chronic disease management across Canada Rheumatoid arthritis redefined Canadian doctor played a major role in international effort to overhaul RA criteria New drugs on the way for gout Experimental compounds control pain and reduce serum uric acid levels Cherries aid gout treatment Consider concentrated juice as an adjunct to urate-lowering therapy, researcher says Drinking decreases arthritis risk Study links alcohol consumption with reduced likelihood of several inflammatory conditions Tech refresher: Helping patients get a grip on arthritis First IL-6 receptor inhibitor for rheumatoid arthritis Hoffmann-La Roche will soon be introducing Actemra (tocilizumab), the first interleukin-6 (IL-6) receptor inhibitor to be approved for the treatment of rheumatoid arthritis (RA). First Previous 19 20 21 22 Next Last
